Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 16/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 15/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932342 | 0.86 | CSNK2A1 (0.76) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL10131714 | 0.81 | CSNK2A1 (0.68) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL629427 | 0.80 | CSNK2A1 (0.67) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2690184 | 0.80 | CSNK2A2 (0.68) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL629013 | 0.80 | CSNK2A2 (0.71) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4970671 | 0.79 | CSNK2A1 (0.81) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL629928 | 0.78 | CSNK2A1 (0.79) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL27375344 | 0.78 | CSNK2A1 (0.63) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL1450504 | 0.76 | CSNK2A1 (0.61) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL8887189 | 0.75 | CSNK2A1 (0.65) | CSNK2A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584265-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052690-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052690-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| EP-2061765-B1 | Serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES INC (TW) | 2014-10-22 | — | — | EP | disclosed |
| EP-2061765-B1 | Serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES INC (TW) | 2014-10-22 | — | — | EP | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2009097014-A2 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| EP-2061765-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | Cylene Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | PACSIN2, CKS1B, CSNK1A1 | CSNK2A1 6/4885CSNK2A2 11/4885CSNK2B 16/4885 |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | CSNK2A1 24/4885CSNK2A2 37/4885CSNK2B 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.